HBMN:SWX
HBM Healthcare Investments AG
CHF 236.50
arrow_upward
+0.64%(+1.50) 1D
6월 12일, 오후 5시 31분 0초 GMT+2 · CHF
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoHBMN의 주요 통계 생성 중...
시가
CHF 233.50
고가
CHF 239.00
저가
CHF 233.50
시가총액
15.94억
평균 거래량
3.30천
거래량
0.00
배당금
3.81%
분기 배당금
CHF 2.25
배당락일
2026. 6. 17.
주가수익률
5.81
52주 최고가
CHF 245.50
52주 최저가
CHF 157.40
EPS
CHF 40.74
유통 주식수
674.00만
시가
CHF 233.50
고가
CHF 239.00
저가
CHF 233.50
시가총액
15.94억
평균 거래량
3.30천
거래량
0.00
배당금
3.81%
분기 배당금
CHF 2.25
배당락일
2026. 6. 17.
주가수익률
5.81
52주 최고가
CHF 245.50
52주 최저가
CHF 157.40
EPS
CHF 40.74
유통 주식수
674.00만
뉴스 기사
웹 소스 기반
프로필
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
HBM Healthcare Investments AG에 관한 정보